BTIG Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $59
Needham Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $66
RxSight's Growth Trajectory: A Buy Recommendation on Strong Revenue Prospects and International Expansion
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $70
RxSight Price Target Raised to $66.00/Share From $54.00 by Needham
RxSight Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and RxSight (RXST)
Needham Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $66
Oppenheimer Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $65
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $54 to $70
RxSight Price Target Cut to $65.00/Share From $72.00 by Oppenheimer
Wells Fargo Reaffirms Their Buy Rating on RxSight (RXST)
Buy Rating Affirmed for RxSight Amidst Robust Growth and Market Expansion
RxSight Analyst Ratings
RxSight (RXST) Gets a Buy From Morgan Stanley
RxSight Analyst Ratings
RxSight Analyst Ratings
Stifel Maintains Buy on RxSight, Lowers Price Target to $70
RxSight's Strong Q1 Performance and Market Expansion Justify Buy Rating
What 10 Analyst Ratings Have To Say About RxSight